The Business Research Company’s report on the Nerve Growth Factor Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the nerve growth factor market’s growth in recent years?
The increasing prevalence of neurological disorders is expected to propel the growth of the nerve growth factor market going forward. Neurological disorders are medical conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities. The increasing prevalence of neurological disorders is due to aging populations and advances in diagnostic technology. Advances in diagnostic technology improve the detection and reporting of these disorders, leading to higher documented incidence rates. Nerve growth factor (NGF) plays a crucial role in the maintenance, survival, and regeneration of neurons, making it a key factor in addressing the prevalence of neurological disorders by promoting neural repair and potentially slowing disease progression. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, dementia (a neurological disorder ) cases in Australia are projected to rise from around 411,100 in 2023 to 849,300 by 2058. Therefore, the increasing prevalence of neurological disorders is driving the growth of the nerve growth factor market.
Access Your Free Sample of the Global Nerve Growth Factor Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22070&type=smp
How does the future projection of the nerve growth factor market size compare to its historical growth?
The nerve growth factor (NGF) market size has grown strongly in recent years. It will grow from $1.11 billion in 2024 to $1.20 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising incidence of traumatic brain injuries, increasing prevalence of neurodegenerative diseases, increasing investment in research and development activities, increasing awareness about nerve regeneration therapies, and increasing incidence of peripheral neuropathy.
The nerve growth factor (NGF) market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to rise in demand for biopharmaceuticals, rise in prevalence of autoimmune neurological disorders, increasing focus on neuroinflammation research, increasing investment in AI-driven drug discovery, and increasing consumer demand for NGF-based therapies. Major trends in the forecast period include advancements in biotechnology, personalized medicine approaches, innovative drug delivery systems, regulatory approvals, and development of nerve growth factor (NGF) antibodies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22070&type=smp
Which key players are shaping the future of the nerve growth factor market?
Major companies operating in the nerve growth factor market are Pfizer Inc., AstraZeneca Plc, Eli Lilly & Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals Inc., Genetech, Dompé farmaceutici S.p.A., Promega Corporation, Akeso Inc, CUSABIO TECHNOLOGY LLC, Staidson Beijing BioPharmaceuticals, Biocare Medical LLC, Beike Biotechnology, Enzo Life Sciences Inc., Genexis Biotech Pvt. Ltd., Mimetogen Pharmaceuticals, Alomone Labs, MimeTech Srl, Herantis Pharma, Prospec-Tany Technogene Ltd., PainCeptor Pharma
What trends will propel the growth and evolution of the nerve growth factor market?
Major companies operating in the nerve growth factor market are focusing on developing advanced products, such as nerve growth factor (NGF) monoclonal antibodies to inhibit NGF. They are aiming to provide effective pain relief. An NGF monoclonal antibody is a biological drug that targets and neutralizes nerve growth factor (NGF) to block receptor interaction, reducing pain and nerve inflammation. It helps regulate pain signaling and nerve cell survival. For instance, in February 2022, Akeso, Inc., a China-based biopharmaceutical company, introduced AK115, a humanized IgG1 monoclonal antibody that received approval from China’s National Medical Products Administration to initiate clinical trials for pain treatment, including cancer pain. AK115 is designed to block NGF interactions with receptors, aiming to relieve pain while offering long-term safety, non-addictiveness, and improved efficacy for opioid-resistant cancer patients. This next-generation analgesic aims to provide long-term, non-addictive pain relief, particularly for opioid-resistant cancer patients, improving their quality of life.
Which regions are expected to become dominant players in the nerve growth factor market?
Asia-Pacific was the largest region in the nerve growth factor market in 2024. The regions covered in the nerve growth factor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/nerve-growth-factor-global-market-report
What are the emerging key segments in the nerve growth factor market, and how are they evolving?
The nerve growth factor market covered in this report is segmented –
1) By Type: Alpha-Nerve Growth Factor (NGF), Beta-Nerve Growth Factor (NGF), Gamma-Nerve Growth Factor (NGF), Other Types
2) By Agents: Cenegermin, Other Agents
3) By Indication: Neurodegenerative Disorders, Spinal Cord Injuries, Eye Disorders, Epithelial Diseases, Tissue Healing, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Alpha-Nerve Growth Factor (a-NGF): Natural Alpha-NGF, Recombinant Alpha-NGF, Synthetic Alpha-NGF, Alpha-NGF For Research Applications
2) By Beta-Nerve Growth Factor (ß-NGF): Human Beta-NGF, Animal-Derived Beta-NGF, Recombinant Beta-NGF, Therapeutic Beta-NGF, Research-Grade Beta-NGF
3) By Gamma-Nerve Growth Factor (?-NGF): Natural Gamma-NGF, Recombinant Gamma-NGF, Synthetic Gamma-NGF, Gamma-NGF for Neurodegenerative Research
4) Other Types: Hybrid NGF Molecules, NGF Mimetics, NGF Gene Therapy-Based Products, NGF-Infused Biomaterials
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22070
What defines the structure and scope of the nerve growth factor market?
Nerve growth factor (NGF) is a type of protein that is essential for the growth, maintenance, and survival of nerve cells, particularly sensory and sympathetic neurons. It plays a crucial role in the development of the nervous system and helps promote the regeneration of nerve cells after injury. Nerve growth factor binds to specific receptors on nerve cells, triggering pathways that support cell survival and differentiation
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
